The in vitro effects of xancor, a synthetic astaxanthine derivative, on hemostatic biomarkers in aspirin-naïve and aspirin-treated subjects with multiple risk factors for vascular disease

American Journal of Therapeutics

Volumn 17, Issue 2, 2010, Pages 125-132

  Serebruany, Victor ^a   Malinin, Alex ^a   Goodin, Thomas ^b   Pashkow, Fredric ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Cardax Pharmaceuticals   (United States)

Author keywords

Antioxidant; Aspirin; Astaxanthine; Cardiovascular; Coagulation; Fibrinolysis; In vitro; Platelets; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBIN III; ARACHIDONIC ACID; ASTAXANTHIN; CD14 ANTIGEN; CD151 ANTIGEN; CD31 ANTIGEN; CD40 LIGAND; CD51 ANTIGEN; CD61 ANTIGEN; CD63 ANTIGEN; COLLAGEN FIBER; D DIMER; FIBRINOGEN; FIBRINOGEN RECEPTOR; FRUCTOSE BISPHOSPHATE; LYMPHOCYTE ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PADGEM PROTEIN; PLASMINOGEN; PROTEIN C; PROTEIN S; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; XANCOR;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CONCENTRATION RESPONSE; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK FACTOR; THROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; VASCULAR DISEASE;

ADULT; ANTIOXIDANTS; ASPIRIN; BIOLOGICAL MARKERS; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PRODRUGS; RISK FACTORS; SINGLE-BLIND METHOD; XANTHOPHYLLS;

EID: 77949967825     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31819cdbbd     Document Type: Article

References (32)

1. World Health Report 2002: Reducing Risk, Promoting Healthy Life. Geneva: World Health Organization; 2002.
2. Tomoaia-Cotisel M, Zsako J, Salajan M, et al. Surface complexes of xanthophyll films with transition metal ions. Physiologie. 1989;26:341-347.
3. Kim JH, Choi SK, Choi SY, et al. Suppressive effect of astaxanthine isolated from the Xanthophyllomyces dendrorhous mutant on ethanol-induced gastric mucosal injury in rats. Biosci Biotechnol Biochem. 2005;69:1300-1305.
4. Vine AL, Leung YM, Bertram JS. Transcriptional regulation of connexin 43 expression by retinoids and carotenoids: similarities and differences. Mol Carcinog. 2005;43: 75-85.
5. Lee SJ, Bai SK, Lee KS, et al. Astaxanthine inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol Cells. 2003;16:97-105.
6. Naito Y, Uchiyama K, Aoi W, et al. Prevention of diabetic nephropathy by treatment with astaxanthine in diabetic db/db mice. Biofactors. 2004;20:49-59.
7. Lyons NM, O,Brien NM. Modulatory effects of an algal extract containing astaxanthine on UVA-irradiated cells in culture. J Dermatol Sci. 2002;30:73-84.
8. Sanocka D, Kurpisz M. Reactive oxygen species and sperm cells. Reprod Biol Endocrinol. 2004;2:12.
9. Garrido N, Meseguer M, Simon C, et al. Pro-oxidative and anti-oxidative imbalance in human semen and its relation with male fertility. Asian J Androl. 2004;6:59-65.
10. Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol. 1994; 31:229-239.
11. Zeidan AM, Kouides PA, Tara MA, et al. Platelet function testing: state of the art. Exp Rev Cardiovasc Ther. 2007;5: 955-967.
12. Serebruany VL, Gurbel PA. The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin? Thromb Haemost. 1999;81:314-316.
13. Margalith PZ. Production of ketocarotenoids by microalgae. Appl Microbiol Biotechnol. 1999;51:431-438.
14. Kikuchi Y, Sato K, Mizuguchi Y. Modified cell-flow microchannels in a single-crystal silicon substrate and flow behavior of blood cells. Microvasc Res. 1994;47:126-139.
15. Marui N, Offermann MK, Swerlick R, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant sensitive mechanism in human vascular endothelial cells. J Clin Investig. 1993;92:1866-1874.
16. Satriano JA, Shuldiner M, Hora K, et al. Oxygen radicals as second messengers for expression of the monocyte chemoattractant protein, JE/MCP-1 and the monocyte colony-stimulating factor, CSF-1, in response to tumor necrosis factor-alpha and immunoglobuolin G. Evidence for involvement of reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidase. J Clin Invest. 1993;92:1564-1571.
17. Ali MH, Schlidt SA, Chandel NS, et al. Endothelial permeability and IL-6 production during hypoxia: role of ROS in signal transduction. Am J Physiol. 1999;277:L1057- 1065.
18. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000; 87:840-844.
19. Narizhneva NV, Razorenova OV, Podrez EA, et al. Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. FASEB J. 2005;19:1158-1160.
20. van der Zijpp YJ, Poot AA, Feijen J. ICAM-1 and VCAM-1 expression by endothelial cells grown on fibronectincoated TCPS and PS. J Biomed Mater Res A. 2003;65:51-59.
21. Gawaz M, Page S, Massberg S, et al. Transient platelet interaction induces MCP-1 production by endothelial cells via I kappa B kinase complex activation. Thromb Haemost. 2002;88:307-314.
22. Mayer K, Merfels M, Muhly-Reinholz M, et al. Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation. Am J Physiol Heart Circ Physiol. 2002;283:H811-818.
23. Chakrabarti S, Varghese S, Vitseva O, et al. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol. 2005;25:2428-2434.
24. Yamashita T, Shoge M, Oda E, et al. The free-radical scavenger, edaravone, augments NO release from vascular cells and platelets after laser-induced, acute endothelial injury in vivo. Platelets. 2006;17:201-206.
25. Hsiao G, Wang Y, Tzu NH, et al. Inhibitory effects of lycopene on in vitro platelet activation and in vivo prevention of thrombus formation. J Lab Clin Med. 2005; 146:216-226.
26. Arnaud J, Bost M, Vitoux D, et al. Société Francophone d,Etudes et de Recherche sur les Eléments Toxiques et Essentiels. Effect of low dose antioxidant vitamin and trace element supplementation on the urinary concentrations of thromboxane and prostacyclin metabolites. J Am Coll Nutr. 2007;26:405-411.
27. Aydogan K, Karadogan SK, Tunali S. Acitretin-induced subungual hemorrhage. Int J Dermatol. 2007;46:494-495.
28. Seishima M, Oda M, Yamanaka S. Thrombocytopenia possibly induced by etretinate in a psoriatic patient. J Dermatol. 2005;32:917-920.
29. Ping D, Boekhoudt G, Boss JM. Trans-retinoic acid blocks platelet-derived growth factor-BB-induced expression of the murine monocyte chemoattractant-1 gene by blocking the assembly of a promoter proximal Sp1 binding site. J Biol Chem. 1999;274:31909-31916.
30. Serebruany VL, Gurbel PA, O,Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharm Res. 2001;43:453-462.
31. Serebruany VL, Malinin AI, Lowry DR, et al. Platelet inhibition by valsartan and valeryl 4-hydroxy valsartan: a possible missing link to explain benefits of angiotensin II receptor blockers in patients after acute vascular events. J Cardiovasc Pharm. 2004;43:677-684.
32. Vaidyanathan S, Camenisch G, Schuetz H, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. 2008;48: 1323-1338.